Is removing SARS-CoV-2 from the blood sufficient to decrease the severity of critically ill COVID patients? This clinical trial aims to test the efficacy of a new blood filter for the treatment of COVID-19
This system developed by ExThera Medical is able to bind to microorganisms in the blood and decrease the amount of viruses or bacteria present.
The Seraph 100 filter consists of a set of small particles made of a material similar to the heparan sulfate in cells. This technology works in a similar way to a hemodialysis system, filtering the blood, with the objective that the microorganisms bind to the filter and are eliminated from the bloodstream. A session of about 4-6h would be enough to clean a large part of the pathogens found in the blood.
This technology was tested by the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense.
Description of the Study:
- Title: Clinical Trial Testing the Efficacy of a New Blood Filter for the Treatment of COVID-19.
- Principal Investigators: Ricard Ferrer Roca, Pilar Giron Espot, Tatiana Acero Bailen and Juan Carlos Ruiz Rodríguez.
- Centers of Implementation: Hospital Vall d’Hebron and Hospital Clínico San Carlos de Madrid.
- Study Population: COVID-19 critically ill patients who are mechanically ventilated and present, in addition to respiratory dysfunction, dysfunction in some other organ.
- Study Type: Multicenter clinical trial.
Objectives of the Study:
Principal Objective: To study whether the Seraph 100 filter can decrease the severity of critically ill patients with COVID-19.
More about this Study:
The Seraph 100, like other types of filters that have been used for years in Intensive Care Units, is not only capable of binding microorganisms but also inflammatory mediators.
The purification system is similar to dialysis, but in this case it is viral particles that may be present in the blood that are purified by the filter.
So far, no side effects associated with the use of this system have been observed, so the researchers consider that it could be a novel treatment opportunity for all those patients critical for infections of different types.